The Role of Clinical Pharmacists in Mitigating Drug-Induced QTc Prolongation: A Cross-Sectional Study
-
Ali Pirsalehi
,
Atieh Mohammadian
,
Zakieh Dehbashi
,
Amir Farrokhian
,
Fatemeh Amin-Dehghan
,
Mohammad Abbasinazari
Abstract
Background: Drug-induced QTc prolongation represents the predominant cause of acquired long QTc syndrome. Pharmacists’ intervention, through the screening of at-risk patients and the provision of recommendations to prescribers for modifying drug regimens, may mitigate the adverse outcomes associated with this condition. This cross-sectional study aimed to evaluate the role of clinical pharmacists in reducing drug-induced acquired long QTc syndrome and mitigating the risk of progression toward life-threatening arrhythmias.
Methods: We included hospitalized patients who were receiving at least two concomitant QT-prolonging medications, or one QT-prolonging medication along with a diagnosis of heart failure, myocardial infarction, or sepsis in the study over three months. Using the Tisdale risk score, we provided recommendations to the prescribing physician, and acceptance rates were recorded. Additionally, the rate of QTc prolongation was assessed in the patients.
Results: The study was completed with 90 patients. The concomitant use of ondansetron and methadone was identified as the most common high-risk drug combination. A total of 56 pharmacist recommendations were made, with an estimated physician acceptance rate of 89%. Additionally, normalization of the QTc interval was observed in 14 out of 22 patients (63.6%) following pharmacists’ intervention.
Conclusion: Clinical pharmacists are instrumental in the prevention of drug-induced long QTc syndrome among hospitalized patients.
Rautaharju PM, Surawicz B, Gettes LS. AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram. Circulation. 2009;119(10): e241-e250.
Aghajani MH, Sistanizad M, Abbasinazari M, Ghamsari MA, Ayazkhoo L, Safi O, et al. Potential Drug-drug Interactions in Post-CCU of a Teaching Hospital. Iran J Pharm Res. 2013;12(1):243-248.
Zhu W, Bian X, Lv J. From Genes to Clinical Management: A Comprehensive Review of Long QT Syndrome Pathogenesis and Treatment. Hear Rhythm O2. 2024;5(8):573–586.
Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE. Mechanisms, Risk Factors, and Management of Acquired Long QT Syndrome: A Comprehensive Review. Sci World J. 2012;2012(1):212178.
Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, et al. Development and Validation of a Risk Score to Predict QT Interval Prolongation in Hospitalized Patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479–487.
E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Guidance Documents. U.S. Food and Drug Administration. [2005 Oct]. Available from: URL: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e14-clinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic-potential-non-antiarrhythmic-0.
Berul CI. Acquired Long QT Syndrome: Definitions, Pathophysiology, and Causes. In: Asirvatham S, Yeon SB, editors. UpToDate. Waltham, MA: Wolters Kluwer (Accessed on May 24, 2024).
Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, et al. Prevention of Torsade de Pointes in Hospital Settings: A Scientific Statement from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2010;121(8):1047–1060.
Francis J, Abraham S. Clinical Pharmacists: Bridging the Gap Between Patients and Physicians. Saudi Pharm J. 2014;22(6):600–602.
Chastang A, Renet S, Corny J, Beaussier H, Petre A, Lillo-Lelouet A, et al. Impact of Hospital Pharmacist Interventions on the Combination of Citalopram or Escitalopram with other QT-prolonging Drugs. Int J Clin Pharm. 2019;41(1):42–48.
Hamza AU, Rizvi K, Ali K. Incorporation of Pharmacist in Conducting Medication Reviews for Identification of Risk of QT Prolongation: A Neglecting Latent Approach in Cardiology. J Pharm Care. 2022;10(3):175-179.
Ng TMH, Bell AM, Hong C, Hara JM, Touchette DR, Danskey KN, et al. Pharmacist Monitoring of QTc Interval–Prolonging Medications in Critically Ill Medical Patients: A Pilot Study. Ann Pharmacother. 2008;42(4):475–482.
| Files | ||
| Issue | Vol 13, No 1 (Winter 2025) | |
| Section | Brief Report | |
| Keywords | ||
| QT Prolongation, Clinical pharmacist, Pharmacist Intervention, Tisdale score | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
